Revenue Growth Driven by Core Business Momentum
Danaher grew total revenue by 3.7% YoY to $5.95B in Q1 2026, up from $5.74B in Q1 2025, suggesting a recovery in demand across its life sciences and diagnostics segments following prior-year headwinds.
DANAHER CORP /DE/ is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: Danaher delivered solid Q1 2026 results with revenue of $5.95B (+3.7% YoY), net income of $1.03B (+7.9% YoY), and diluted EPS of $1.45 (+9.8% YoY), reflecting disciplined cost management and improving profitability despite a slight gross margin compression.
Drawn from management commentary in the Q1 2026 10-Q:
Danaher grew total revenue by 3.7% YoY to $5.95B in Q1 2026, up from $5.74B in Q1 2025, suggesting a recovery in demand across its life sciences and diagnostics segments following prior-year headwinds.
Operating income rose 5.5% YoY to $1.34B while SG&A expenses were nearly flat at $1.86B (+0.1% YoY), demonstrating strong operating leverage as revenue growth outpaced cost growth and lifted operating margin to 22.6% from 22.2%.
Gross margin declined modestly to 60.3% from 61.2% a year ago, as cost of revenue grew 5.8% YoY — faster than revenue growth of 3.7% — indicating some input cost or mix pressures that management will need to monitor.
Revenue
$5.95B
++3.66% YoY
EPS (Basic)
$1.45
++9.02% YoY
Gross Margin
60.3%
-0.81% YoY
Operating Income
$1.34B
++5.49% YoY
Add DHR to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.